From: Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients
Characteristics | CRC patients | P-value | |
---|---|---|---|
 | KRAS-mutated (n=101) | KRAS wild-type (n=234) |  |
Age | 0.61 | ||
 [Median (IQR)] (year) | 61 (49,68) | 59.5 (51.25,67.75) |  |
Sex | 0.85 | ||
 Male | 62 (30.5) | 141 (69.5) |  |
 Female | 39 (29.5) | 93 (70.5) |  |
Primary site | 0.19 | ||
 Rectum | 49 (33.8) | 96 (66.2) |  |
 Left colon | 22 (23.2) | 73 (76.8) |  |
 Transverse colon | 11 (40.7) | 16 (59.3) |  |
 Right colon | 19 (27.9) | 49 (72.1) |  |
Pathological T classification | 0.36 | ||
 T1-2 |  15 (36.6) | 26 (63.4) |  |
 T3-4 | 86 (29.7) | 204 (70.3) |  |
Pathological N classification | 0.95 | ||
 N0 | 53 (30.5) | 121 (69.5) |  |
 N1-2 | 44 (30.8) | 99 (69.2) |  |
M classification | 0.02* | ||
 M0 | 83 (43.5) | 108 (56.5) |  |
 M1 | 18 (27.3) | 48 (72.7) |  |
Pathological stage | 0.85 | ||
 I-II | 47 (30.5) | 107 (69.5) |  |
 III-IV | 52 (31.5) | 113 (68.5) |  |
Leukocyte (109/L) | 6.70±2.16 | 6.85±2.60 | 0.614 |
Blood platelet (109/L) | 283.94±99.25 | 292.55±108.71 | 0.495 |
Neutrophil (109/L) | 3.82±2.24 | 4.36±3.53 | 0.157 |
Lymphocyte (109/L) | 1.63±0.61 | 1.79±1.37 | 0.260 |
Albumin (g/L) | 18.73±10.46 | 22.76±28.45 | 0.167 |
Total T lymphocyte (%) | 65.77±9.76 | 65.58±1034 | 0.877 |
Helper T lymphocyte (%) | 40.00±7.34 | 39.13±8.68 | 0.374 |
Suppressor t lymphocyte (%) | 20.38±.82 | 20.67±7.27 | 0.739 |
Natural killer cell (%) | 14.17±8.01 | 14.04±7.31 | 0.888 |
B-lymphocyte (%) | 12.48±5.71 | 11.96±7.25 | 0.518 |
Immunoglobulin G (g/L) | 11.86±3.12 | 11.54±2.98 | 0.369 |
Immunoglobulin M (g/L) | 0.91±0.40 | 1.08±0.94 | 0.024* |
Immunoglobulin A (g/L) | 2.51±1.18 | 2.44±0.98 | 0.617 |
Complement C3 (g/L) | 0.95±0.20 | 0.99±0.24 | 0.134 |
Complement C4 (g/L) | 0.25±0.09 | 0.25±0.10 | 0.909 |
CRP (mg/L) | 7.07±9.20 | 10.61±18.43 | 0.020* |
hs-CRP (mg/L) | 1.60±2.19 | 2.43±4.33 | 0.020* |